Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): A post hoc analysis of the SUNSHINE and SUNRISE trials.

J Eur Acad Dermatol Venereol · 2025 · PMC12291009 · PMID 39425517

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The IHS4‐55, IHS4‐75 and IHS4‐90 responses observed at Week 16 showed a trend towards further improvement at Week 52 in patients receiving secukinumab treatment.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.